Presbyopia Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgical Treatment, Corrective Lenses, Pharmacological Treatment), By End-User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers (ASCs), Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Presbyopia Treatment Market Size

The global presbyopia treatment market size was valued at USD 10.73 billion in 2025 and is projected to grow from USD 11.32 billion in 2026 to USD 17.37 billion by 2034, registering a CAGR of 5.5% during the forecast period from 2026 to 2034. North America dominated the presbyopia treatment market with a market share of 38.2% in 2025.

The market is experiencing significant growth, driven by the rising geriatric population with eye-related issues, increasing screen time, and heightened awareness about presbyopia treatment options. Presbyopia, a condition that affects near vision, can be managed through various ophthalmic and surgical treatments. The main treatment modalities include glasses, such as reading glasses or bifocals/progressive lenses, and contact lenses, which can be multifocal or monovision lenses.

In addition to these, surgical procedures and minimally invasive therapies are gaining popularity as effective treatment options. The growing demand for eye care services, the increasing prevalence of digital eye strain, and ongoing R&D efforts focused on novel solutions are further propelling market growth. Notably, the development of pharmacological treatments, such as miotics like pilocarpine, has shown promising results in improving near vision through the pinhole effect.

A systematic review published in November 2024 highlighted the progress in this area, showcasing the potential of miotics in managing presbyopia. These advancements in research and development play a crucial role in shaping the market. By improving the convenience and accessibility of treatments for patients, ongoing innovation is not only driving market growth but also enhancing the quality of life for individuals affected. As these developments continue to evolve, the market is poised for sustained expansion.

Treatment Insights

The corrective lenses segment dominates the global market, leading in revenue due to their affordability, ease of use, and non-invasive nature. Corrective lenses, including reading glasses, bifocals, and multifocal contact lenses, are preferred for their immediate results and wide availability.

• For instance, a 2023 ESCRS Clinical Trends Survey revealed that 42% of surgeons preferred trifocal lenses for presbyopia correction, highlighting their effectiveness.

The rising adoption of second-generation intraocular lenses (IOLs) for surgical treatments further fuels the market, enhancing vision at multiple focal points and driving demand.

Request Customizationto receive a tailored report.

End-User Insights

Hospitals hold the largest market share, driven by the growing prevalence of eye conditions, advanced diagnostic tools, and skilled ophthalmologists. Hospitals are often the first point of contact for presbyopia patients, offering a comprehensive range of services, from corrective glasses to surgical and pharmaceutical treatments. The presence of state-of-the-art equipment and specialized care contributes to the growing preference for hospital-based treatments. Moreover, hospitals are pivotal in providing a seamless experience, combining diagnostic, treatment, and follow-up care to effectively manage presbyopia.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America holds a dominant position in the global presbyopia treatment market, driven by a high incidence of presbyopia, advanced healthcare infrastructure, and rapid adoption of innovative treatments. The region's strong market growth is supported by the high penetration of novel interventions such as pharmaceutical treatments and advanced surgical options.

Moreover, rising awareness, favorable reimbursement policies, and increasing demand for premium intraocular lenses (IOLs) are all key factors propelling market expansion. With a well-established healthcare system and a large aging population, North America remains a hub for presbyopia treatments, ensuring continued growth.

The U.S. market is leading, fueled by its advanced healthcare infrastructure and the growing prevalence of presbyopia. As of August 2023, the AOA Health Policy Institute reported that 128 million Americans (over 90% of adults aged 45 and older) are affected. This substantial patient base, coupled with access to advanced treatments, presents a significant opportunity for market growth in the U.S., driving demand for innovative solutions.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Presbyopia Treatment Market Trends

Asia-Pacific region is projected to witness the highest CAGR, driven by the rapidly aging population, a surge in the prevalence of eye diseases, and increasing healthcare expenditures. Additionally, the growing adoption of advanced ophthalmic products, improved availability of treatments, and rising disposable incomes contribute to the market's expansion. Countries like China, Japan, and India are at the forefront, with a growing awareness of presbyopia and the increasing demand for both traditional and advanced treatment options, positioning Asia-Pacific as a dynamic and rapidly evolving market.

China market is gaining momentum due to advancements in infrastructure, research, and clinical trials. In October 2024, Corxel and Lenz Therapeutics reported successful Phase 3 trial results for LNZ100, a presbyopia eye drop formulation. The trial showed promising results, with 69% of patients experiencing significant near vision improvement. This non-invasive, reversible treatment presents a breakthrough alternative to eyeglasses, propelling the demand for advanced ophthalmic solutions in China’s growing market.

India’s presbyopia treatment industry is experiencing rapid expansion, driven by government initiatives and regulatory advancements. In September 2024, Entod Pharmaceuticals received approval from the Drug Controller General of India (DCGI) for PresVu, the first topical presbyopia treatment in the country. This approval significantly reduces the dependence on reading glasses, making India a key innovator in ophthalmic drug development and further fueling the growth of the market in the region.

Europe Presbyopia Treatment Market Trends

Germany remains a key player in Europe's market, driven by significant investments in research and government initiatives. In July 2022, the German Federal Ministry of Education and Research (BMBF) funded a groundbreaking laser eye surgery research project by SCHWIND eye-tech solutions with €1.6 million in investments. This initiative enhances treatment accessibility, expanding Germany's market for presbyopia treatment.

In France, the presbyopia treatment industry is bolstered by increasing incidences of the condition and strong government support. In January 2025, Laclarée, based in Villeurbanne, secured €3.5 million in seed funding to develop autofocusing spectacles for presbyopia, which are expected to hit the market by mid-2026. Such innovative projects, combined with governmental funding, are positioning France for significant growth in the presbyopia treatment sector, driving further market advancements.

Company Market Share

Key players in the market are actively adopting strategic business initiatives such as collaborations, mergers and acquisitions, product approvals, and innovative product launches to strengthen their market presence. By forging partnerships with research institutions, investing in advanced technologies, and expanding their product portfolios, companies aim to enhance treatment efficacy and accessibility.

Allergan: An Emerging Player in the Global Presbyopia Treatment Market

Allergan, a globally recognized pharmaceutical company, specializes in eye care, aesthetics, neurosciences, and gastroenterology. It is primarily focused on developing and commercializing branded prescription drugs, biologics, and regenerative medicines. With a strong research-driven approach, Allergan has introduced innovative treatments for ophthalmic conditions, including presbyopia.

Recent Developments by Allergan:

• In October 2021, Allergan (a subsidiary of AbbVie) announced that the U.S. Food and Drug Administration (FDA) cleared VUITY (pilocarpine HCl ophthalmic solution) 1.25% presbyopia in adults, also known as blurry near vision due to age.

List of Key and Emerging Players in Presbyopia Treatment Market